Press release


07/05/2012
Oryzon presents its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
Logo Oryzon
Oryzon announced today that Dr. Tamara Maes will present the latest advances of its LSD1 program in hematological malignancies at GTC’s 2nd Epigenetics in Drug Discovery conference in the session Drug Discovery in Epigenetics: on May 30-31 at the Hyatt Harborside in Boston, MA.
 
Barcelona, May 7th, 2012. Dr. Maes' presentation will occur on May 30th at 16:45 pm under the title “Strong and specific LSD1 inhibitors for treatment of hematological malignancies”. Drugs against LSD1 have been shown to be effective in the treatment of acute leukemia. These preclinical findings have been reported by two British independent groups in recent issues of Nature Medicine and Cancer Cell.
Molecules discovered and developed by Oryzon were efficient in the treatment of acute myeloid leukemia (AML), which represents 40% of all leukemias in humans, and especially an aggressive form of acute myeloid leukemia called mixed lineage leukemia (MLL), pointing to a significant potential therapeutic window for the use of LSD1 inhibitors in the MLL molecular subtype of AMLs. Oryzon’s scientists have shown also that LSD1 inhibition could also be efficacious in the treatment of Acute Lymphoblastic Leukemia (ALLs), which represents 25% of juvenile leukemia, and in certain types of multiple myeloma and Chronic Lymphocytic leukemia. These promising results open new avenues to treat these cancers. Oryzon’s drug discovery program in LSD1 has yielded enantiomerically pure, potent and selective LSD1 inhibitors that are >1000x stronger than Parnate™ (tranylcypromine), highly selective over related enzymes MAO-A/B, have excellent pharmacological characteristics and are active in vivo at doses of down to 0.05mpk. The company expects to move its compounds to Clinical Phase I/IIa early next year.
 
 
 
 
Permalink  
 
Developed by Web4Bio